Danting Jiang
Co‑Founder and CEO
Vivere Oncotherapies
Vivere Oncotherapies provides engineered biologic therapies that deliver immune‑activating payloads directly to solid tumors, converting immunologically cold lesions into responsive sites. Their CRISPR‑based oncolytic virotherapy platform enables precise tumor targeting and enhanced safety, offering a delivery solution for pharma and biotech oncology programs.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Laura Toline Kovacs
Co‑Founder and CTO
Theresa Roth
Co‑Founder
Melissa Kotterman
Founder
Product
Problem
Solid tumors that are immunologically “cold” evade detection by the body’s immune system, limiting the effectiveness of existing immunotherapies. Current delivery methods for immune‑activating agents often lack precision, resulting in suboptimal tumor targeting and safety concerns.
Solution
Vivere Oncotherapies uses a proprietary bioengineering platform, originally developed at UC Berkeley, to create engineered biologic therapies that precisely deliver immune‑activating payloads to solid tumors. The platform enables targeted activation of a patient’s own immune cells within the tumor microenvironment, converting cold tumors into immunologically active sites. By improving delivery precision and safety, Vivere’s therapies aim to overcome tumor tolerance and provide effective treatment options for cancers with few existing therapies. The approach integrates advanced CRISPR‑based engineering of oncolytic virotherapies to enhance specificity and potency while minimizing off‑target effects.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing oncology pipelines, as well as academic research groups seeking advanced delivery platforms for cancer immunotherapy.
Features
- Proprietary bioengineering platform that designs safe, targeted biologic agents for solid tumors
- CRISPR‑engineered oncolytic virotherapies that selectively infect and modulate tumor cells
- Enhanced delivery mechanisms that focus therapeutic activity within the tumor microenvironment
- Ability to convert immunologically “cold” tumors into immune‑responsive lesions
- Platform flexibility to incorporate different therapeutic modalities for synergistic effects